Alogliptin/pioglitazone

Drug Profile

Alogliptin/pioglitazone

Alternative Names: Alogliptin/Actos; Incresync; Liovel HD; Liovel LD; NesinaAct; Oseni; Pioglitazone/alogliptin; SYR 322/pioglitazone

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Piperidines; Pyrimidinones; Small molecules; Thiazolidinediones
  • Mechanism of Action CD26 antigen inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 17 Aug 2017 Alogliptin/pioglitazone market licensed to Hikma Pharmaceuticals in Middle East and North Africa
  • 15 Dec 2016 Biomarkers information updated
  • 22 Jun 2015 Launched for Type-2 diabetes mellitus in Croatia, Estonia, Finland, Hungary, South Korea, Latvia, Ireland, Italy, Lithuania, Slovakia, Slovenia, Malta, Sweden, Australia, Austria, Denmark and Hong Kong (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top